Differentiation

• Focusing on science, while prioritizing the target and drugs based on real world business opportunities..
• Building a solid management team in-house, and making efficient use of consultants, scientific advisors and other strategic partners where needed
• De-risking our drug development by focusing on non-traditional funding and business models